Post Profile






Thousands of European melanoma patients lack access to new drugs

COPENHAGEN (Reuters) - More than a quarter of European patients with advanced melanoma lack access to new treatments that could extend their lives, according to findings presented at a major cancer conference on Friday.
read more

share

Related Posts


James Graham Brown Cancer Center Becomes First Site in Kentucky Providing Keytruda, Newly FDA-Approved for Melanoma

Health : Newswise Medical News

A newly FDA-approved treatment for patients with advanced or inoperable melanoma who are no longer responding to other drugs is now available to patients at the University of Louisville's James Graham Brown Cancer Center, a part of ...

Research Shows Gene Removal May Aid Melanoma Treatment

Health : Newswise Medical News

There are nearly 10,000 melanoma deaths in the U.S. each year, and while treatment advances have been made, a majority of melanoma patients will die from their disease. Building on these advances, Rutgers Cancer Institute of New Jer...

New Melanoma Drugs Beat Chemotherapy in Trials

Health : Time: Healthland

In two large-scale trials, new drugs made by GlaxoSmithKline extended the lives of patients with advanced melanoma longer than standard chemotherapy. The drugs work by blocking the effect of the BRAF gene mutation, which is present ...

Breast Cancer Patients Live Nearly Six Months Longer With New Precision Drug Compared To Current Treatment Option

Health : Medical News Today

Data from the Phase III EMILIA study, presented at the European Society for Medical Oncology (ESMO) show that T-DM1 (trastuzumab emtansine) prolongs the lives of patients with advanced HER2-positive breast cancer when compared with ...

Thousands of melanoma patients in Europe have no access to new life saving drugs

Health : EurekAlert: Health

(European Society for Medical Oncology) Over 5,000 patients with metastatic melanoma in Europe are denied access to new, life saving drugs every year, according to a survey presented at the ESMO 2016 Congress in Copenhagen.

Comments


Copyright © 2016 Regator, LLC